Guidelines for risk management in patients with, or at risk of inheriting, hereditary cancer predisposition syndromes, should be evidence-based. Furthermore, in the NHS context, they should consider the clinical and cost-effectiveness of any recommended interventions. Scenarios may arise where recommendations put forward by international groups, or suggested based on research studies, may require adaptation before adoption within our health service, if at all. Where necessary, the UKCGG has written responses to recommendations from other groups, bearing in mind the supporting data underpinning such recommendations, as well as the specific needs of and demands on our national clinical and laboratory services.
Loading...